Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01915277 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics

A Phase 1 study, sponsored by Carelon Research.

Completed
Registry status
Phase 1
Development phase
119
Enrollment target

NCT01915277: Completed Phase 1 study, sponsored by Carelon Research.

NCT01915277 is a Phase 1 study that has completed, run by Carelon Research. The registered enrollment target is 119 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01915277, a Phase 1 study, has completed, sponsored by Carelon Research.

COMPLETED
Registry status
Phase 1
Development phase
119 participants
Enrollment target

Study Summary

The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for congenital cardiac problems. This study will also design and validate a dosing schema for the use of DEX as described above.

Primary Outcome

The occurrence of any of the following that is possibly, probably, or definitely related to DEX administration: * Bradycardia * Heart block * Junctional rhythm * Hypotension * Excessive sedation * Cardiac arrest or ECMO cannulation * Serious Adverse Event (SAE) Both the DEX dose, and DEX exposure will be assessed for associations with the primary outcome.

Interventions

  • DRUG Dexmedetomidine

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2014-04-02
Est. Completion 2017-10-17
Phase Phase 1
Carelon Research

50 total trials

What the finished NCT01915277 record still lists

NCT01915277 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher).

The record links to 0 conditions, and to 1 intervention - of which Dexmedetomidine is the first listed.

NCT01915277 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01915277 about?

NCT01915277 is a clinical study titled "A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics". The purpose of this Phase I study is to determine the safety of a drug called dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for neonates and infants undergoing corrective cardiac surgery that requires the use of cardiopulmonary bypass for congenital cardiac pro...

What is the current status of trial NCT01915277?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2014-04-02. Estimated completion is 2017-10-17.

What interventions are being tested in trial NCT01915277?

The interventions under investigation include: Dexmedetomidine (DRUG).

Who is sponsoring clinical trial NCT01915277?

This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01915277's enrollment target sits among peer trials

119 498th of 2000 higher than 1,502 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04870762 · 119 participants · Phase 2

    Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

  • NCT05559853 · 119 participants

    Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

  • NCT06564389 · 119 participants · Phase 1

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • NCT06742801 · 119 participants · NA

    Onyx™ Liquid Embolic IDE Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01915277, the US trial registry maintained by the National Library of Medicine. NCT01915277 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.